D-Thioctic Acid

Cancer

Ain Shams UniversitySmall moleculePhase 4 / ApprovedActive

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 89/ 100

Competitive context

1379 Active assets in the Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Pyridoxol M.D. Anderson Cancer Center	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Propofol Hong Kong Children's Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

D-Thioctic Acid is also rated in:

migraine disorderDormant

BB

Indicative · Phase 4

69 / 100

chronic progressive multiple sclerosisDormant

BB

Indicative · Phase 2/3

67 / 100

nervous system disorderActive

BB

Indicative · Phase 4

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.